Targacept: Targeting Neuronal Nicotinic Receptors NNRs

Targacept is the leading CNS-focused biopharmaceutical company with an extensive portfolio of candidates for first-in-class therapies

Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics(TM), a new class of drugs for the treatment of multiple diseases and disorders of the central nervous system. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity.

We currently have a robust clinical-stage product pipeline and multiple preclinical product candidates. Our most advanced product candidates are in development as treatments for Alzheimer's disease and cognitive dysfunction in schizophrenia, depression and anxiety disorders, and pain.

Targacept is located in Winston-Salem, North Carolina.

		On May 29, 2008, The Scientist, magazine of the life sciences, listed Targacept among the "Best Places to Work in Industry" in its 6th annual survey. Learn more.

		Targacept has several product candidates in clinical development. View our pipeline to learn more.

		Watch the animation to find out how our drugs work in the nervous system.


	August 05, 2008 Targacept Reports Second Quarter 2008 Financial Results
	July 21, 2008 Targacept Initiates Phase 2b Clinical Trial of TC-5214 as Augmentation Treatment in Major Depressive Disorder
	June 25, 2008 Targacept Set to Join Russell 3000 Index
	June 10, 2008 Targacept and AstraZeneca Initiate Clinical Trial of AZD3480 in Adult ADHD

Licensing Opportunities